Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Mudcat who wrote (30201)	1/13/2000 11:24:00 AM
From: bob zagorin	Respond to of 32384

do we know that Pan sales are not good? or are you just speculating.

To: Mudcat who wrote (30201)	1/13/2000 12:18:00 PM
From: Torben Noerup Nielsen	Read Replies (3) \| Respond to of 32384

Mudcat, You're right and I was probably too flippant. It's just that I do not see Panretin as more than a minor contributor at this stage. It was important to Ligand since it was the first drug they got through the FDA. Remember also that AIDS was a pretty popular disease when they were developing it. My impression is that AIDS has faded from the public attention a bit. The public is not known for long attention spans after all and AIDS doesn't seem to happen to ``nice" people while diseases like cancer and diabetes do. No, this is not my opinion of AIDS; I'm worried about it for a lot of reasons. But as far as I can tell, that's what the general public thinks. Anyway, I apologize for being a bit too flippant. An accounting of where Panretin really is would clear the air. Thanks, Torben P.S. I'm really neither on the nay or the yeay side; I'm just watching and trying to keep an even temper. Kind of hard with several rug rats running around the house :-)